Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating potential misleading statements and omissions by Beta Bionics, Inc. that may have violated federal securities laws, following a significant drop in the company's stock price after disappointing financial results were announced [1][3]. Company Overview - Beta Bionics is a medical device company focused on designing, developing, and commercializing solutions for individuals with diabetes who require insulin [2]. Financial Performance - On January 8, 2026, Beta Bionics reported preliminary, unaudited topline financial results for Q4 2025, indicating at least 5,581 new patient starts, which fell short of the consensus expectation of 6,078 [3]. - Following the announcement, Beta Bionics' stock price decreased by approximately $11.85, or 37%, closing at $20.14 on January 9, 2026 [3].

Core Viewpoint - Beta Bionics, Inc. has faced significant stock declines following disappointing preliminary fourth-quarter 2025 performance metrics, raising concerns among investors regarding the company's growth prospects [4][5]. Group 1: Company Performance - On January 9, 2026, Beta Bionics reported lower-than-expected new patient starts for its iLet automated insulin delivery system, which contributed to investor concerns about near-term adoption trends and revenue growth [5]. - Following the announcement, Beta Bionics' stock price dropped approximately $11.85, or 37.04%, closing at $20.14 on the same day [5]. Group 2: Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics for investors who suffered significant losses due to the stock's decline [2][4]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. due to significant stock losses and possible misleading statements made by the company [2][5]. Group 1: Company Overview - Beta Bionics, Inc. is listed on NASDAQ under the ticker BBNX [2]. - The company experienced a significant stock decline of approximately 37% on January 9, 2026, following an announcement regarding lower-than-expected patient starts for the fourth quarter [5]. Group 2: Legal Investigation - The investigation by Faruqi & Faruqi focuses on whether Beta Bionics issued misleading statements or failed to disclose important information that could affect investors [5]. - Investors who suffered significant losses are encouraged to contact Faruqi & Faruqi for discussions regarding their legal rights [1].

IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 financial results after the financial markets close on Tuesday, February 17, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s fourth quarter and full year 2025 ...

Core Viewpoint - DJS Law Group is investigating Beta Bionics, Inc. for potential violations of securities laws following a significant drop in share price due to disappointing patient start forecasts [1][2]. Investigation Details - The investigation centers on whether Beta Bionics made misleading statements or failed to disclose critical information to investors [2]. - On January 8, 2026, Beta Bionics announced an expectation of fewer patient starts in Q4 than analysts had estimated, leading to a 37% decline in share price on January 9, 2026 [2]. DJS Law Group's Focus - DJS Law Group aims to enhance investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation [3]. - The firm represents some of the largest hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [3].

Core Viewpoint - Beta Bionics, Inc. has faced significant stock decline following disappointing preliminary fourth-quarter 2025 performance metrics, raising concerns among investors regarding the company's growth prospects [4][5]. Group 1: Company Performance - On January 9, 2026, Beta Bionics reported lower-than-expected new patient starts for its iLet automated insulin delivery system, which contributed to investor concerns about near-term adoption trends and revenue growth [5]. - Following the announcement, Beta Bionics' stock price dropped by approximately $11.85, or 37.04%, closing at $20.14 [5]. Group 2: Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics due to the significant losses suffered by investors [2]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Viewpoint - Beta Bionics, Inc. is under investigation for potentially issuing misleading statements and failing to disclose important information to investors, leading to a significant drop in its stock price by approximately 37% [2]. Group 1: Company Overview - Beta Bionics, Inc. is listed on NASDAQ under the ticker BBNX [1]. - The company experienced a sharp decline in its stock price, dropping around 37% on January 9, 2026, following an announcement regarding lower-than-expected patient starts in the fourth quarter [2]. Group 2: Legal Investigation - The investigation by Faruqi & Faruqi, LLP focuses on whether Beta Bionics misled investors or failed to disclose critical information [2]. - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [1].

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Beta Bionics, Inc. ("Beta Bionics†or the "Company†) (NASDAQ: BBNX) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BETA BIONICS, INC. (BBNX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On January 8, 2026, Beta Bionics released preliminary fourth q. ...

Group 1 - The article discusses an opportunity for BBNX investors to participate in a fraud investigation led by the Schall Law Firm [1] - The investigation is focused on Beta Bionics, Inc., suggesting potential legal issues surrounding the company [1] - The involvement of a law firm indicates that there may be significant concerns regarding the company's practices or disclosures [1] Group 2 - The announcement highlights the legal landscape surrounding BBNX and its implications for investors [1] - The investigation may uncover critical information that could affect the company's stock performance and investor sentiment [1] - Investors are encouraged to consider their options in light of the ongoing investigation [1]

Market Performance - U.S. stocks showed positive movement, with the Nasdaq Composite gaining approximately 150 points on Friday [1] - The Dow increased by 0.38% to 49,453.05, while the NASDAQ rose by 0.66% to 23,635.11, and the S&P 500 climbed 0.48% to 6,954.85 [1] - European shares also experienced gains, with the eurozone's STOXX 600 up by 0.91% and other major indices like Spain's IBEX 35 and London's FTSE 100 also rising [6] - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 1.61% and China's Shanghai Composite rising 0.92% [7] Sector Performance - Utilities sector shares increased by 1.5% on Friday, while health care stocks saw a decline of 0.5% [1] Commodity Prices - Oil prices rose by 2.7% to $59.34, gold increased by 1.2% to $4,514.50, silver surged by 6.3% to $79.895, and copper rose by 2% to $5.9150 [5] Company News - Rich Sparkle Holdings Ltd shares surged 115% to $52.00 after signing a $39 million offering of 3 million ordinary shares at $13 per share [9] - Quanterix Corp shares increased by 31% to $8.54 following the appointment of a new CEO [9] - CG Oncology Inc shares rose by 24% to $52.18 after announcing an expedited timeline for clinical trial data [9] - Aquestive Therapeutics Inc shares dropped 40% to $3.72 due to FDA identified deficiencies [9] - Pacira Biosciences Inc shares fell 13% to $22.70 after reporting preliminary FY25 revenue results [9] - Beta Bionics Inc shares decreased by 31% to $21.98 following preliminary fourth-quarter financial results [9] Economic Indicators - Nonfarm payrolls increased by 50,000 in December, slightly below expectations [10] - The unemployment rate decreased to 4.4%, below expectations of 4.5% [10] - Average hourly earnings rose by 0.3%, matching forecasts [10] - Housing starts declined by 4.6% to an annualized rate of 1.246 million units [10] - Building permits fell by 0.2% to an annualized rate of 1.412 million [10] - The University of Michigan's consumer sentiment index rose to 54.0, the highest since September 2025 [2][10]